Worth reading
67In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
11.8
Year-on-year change in operating income (%)Wording
Conditional
How definitive the wording is.Results for this period
Full year1 April 2025–31 March 2026ConsolidatedIFRSNet Sales1,131,877¥ millionYear on year +9.2%Progress 91.4%
Operating profit176,320¥ millionYear on year +11.8%Progress 78.5%
Ordinary income178,252¥ millionYear on year +15.3%
Net income attributable to owners of the parent135,914¥ millionYear on year +16.2%Progress 82.2%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥92.14
Operating Margin15.6％
Financial position at period-end
Total assets2,312,234¥ million
of which net assets 1,584,509 ¥ millionEquity ratio 68.5%vs. prior year-end -6.3pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+230,852
Investment-344,102
Financials+155,503
Net change+42,253
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥280,494 million
Segment revenueCardiovascular Company ¥676,421 million (YoY +8.3%), Medical Care Solutions Company ¥216,138 million (YoY +2.3%), Blood and Cell Technologies Company ¥231,037 million (YoY +15.4%), Organ Technologies Business ¥7,985 million
Segment profitName Cardiovascular Company / Current fiscal year ¥163,994 million / Prior-year period ¥154,682 million / yoy_pct Not disclosed, Name Medical Care Solutions Company / Current fiscal year ¥21,568 million / Prior-year period ¥22,993 million / yoy_pct Not disclosed, Name Blood and Cell Technologies Company / Current fiscal year ¥33,635 million / Prior-year period ¥26,482 million / yoy_pct Not disclosed, Name Organ Technologies Business / Current fiscal year ¥1,665 million / Prior-year period Not disclosed / yoy_pct Not disclosed
Regional sales¥443,405 million (YoY +12.1%), ¥242,655 million (YoY +11.2%), ¥91,309 million (YoY +7.5%), ¥131,902 million (YoY +9.9%), ¥222,603 million (YoY +2.5%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥1,239,000 million (YoY +9.5%)
Operating profit¥224,500 million (YoY +27.3%)
Ordinary incomeNot disclosed
Net income¥165,300 million (YoY +21.6%)
Adjusted operating profit¥261,500 million (YoY +19.2%)
Annual Dividend Forecast¥26 → ¥36
Payout ratioFiscal year ending March 2026 32.6％ / Forecast for the fiscal year ending March 2027 32.1％
Shareholder Return PolicyConsider share repurchases with a target total payout ratio of 50%
Factors Behind Changes in Business Performance
Sales remained strong due to continued growth in global healthcare demand, growth in the core businesses, particularly in the Americas, accelerated expansion of the interventional systems business and plasma innovation business, and growth in the pharmaceutical solutions business.
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 Not disclosed
Changes in the scope of consolidationNew Number of companies 1 / Company name OrganOx Limited / Excluded Number of companies 1 / Company name Kalila Medical, Inc.
Material subsequent eventsOn 28 April 2026, the payment date, the Company issued unsecured USD-denominated straight bonds with a total value of US$500 million. The proceeds will be used for general corporate purposes and to refinance part of the funds used to acquire OrganOx.
Impairment lossTotal ¥11,363 million / Subject assets ¥4,520 million, ¥2,238 million, ¥2,084 million, ¥1,423 million
Breakdown of extraordinary income (loss)Extraordinary income Not disclosed / Extraordinary loss Not disclosed / Temporary gains and losses ¥-18,828 million
Depreciation and amortization¥95,379 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for securities analysts and institutional investors)
Issued Shares at Period-End1,480,559,680
Treasury Shares at Period-End5,476,639
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥1,131,877 million (YoY +9.2%) |
| Operating profit | ¥176,320 million (YoY +11.8%) |
| Ordinary income | ¥178,252 million (YoY +15.3%) |
| Profit attributable to owners of the parent | ¥135,914 million (YoY +16.2%) |
| Net income per share | ¥92.14 |
| Operating Margin | 15.6％ |
| Equity ratio | End of the current fiscal period 68.5％ / End of previous period 74.8％ |
| Total assets | ¥2,312,234 million |
| Net assets | ¥1,584,509 million |
| Cash flows from operating activities | ¥230,852 million |
| Cash flows from investing activities | ¥-344,102 million |
| Cash flows from financing activities | ¥155,503 million |
| Cash and cash equivalents at end of period | ¥280,494 million |
| Full-year earnings forecast | Net Sales ¥1,239,000 million (YoY +9.5%) / Operating profit ¥224,500 million (YoY +27.3%) / Ordinary income Not disclosed / Net income ¥165,300 million (YoY +21.6%) / Adjusted operating profit ¥261,500 million (YoY +19.2%) |
| Annual Dividend Forecast | ¥26 → ¥36 |
| Payout ratio | Fiscal year ending March 2026 32.6％ / Forecast for the fiscal year ending March 2027 32.1％ |
| Shareholder Return Policy | Consider share repurchases with a target total payout ratio of 50% |
| Segment revenue | Cardiovascular Company ¥676,421 million (YoY +8.3%), Medical Care Solutions Company ¥216,138 million (YoY +2.3%), Blood and Cell Technologies Company ¥231,037 million (YoY +15.4%), Organ Technologies Business ¥7,985 million |
| Segment profit | Name Cardiovascular Company / Current fiscal year ¥163,994 million / Prior-year period ¥154,682 million / yoy_pct Not disclosed, Name Medical Care Solutions Company / Current fiscal year ¥21,568 million / Prior-year period ¥22,993 million / yoy_pct Not disclosed, Name Blood and Cell Technologies Company / Current fiscal year ¥33,635 million / Prior-year period ¥26,482 million / yoy_pct Not disclosed, Name Organ Technologies Business / Current fiscal year ¥1,665 million / Prior-year period Not disclosed / yoy_pct Not disclosed |
| Regional sales | ¥443,405 million (YoY +12.1%), ¥242,655 million (YoY +11.2%), ¥91,309 million (YoY +7.5%), ¥131,902 million (YoY +9.9%), ¥222,603 million (YoY +2.5%) |
| Depreciation and amortization | ¥95,379 million |
| Impairment loss | Total ¥11,363 million / Subject assets ¥4,520 million, ¥2,238 million, ¥2,084 million, ¥1,423 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Not disclosed / Temporary gains and losses ¥-18,828 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New Number of companies 1 / Company name OrganOx Limited / Excluded Number of companies 1 / Company name Kalila Medical, Inc. |
| Material subsequent events | On 28 April 2026, the payment date, the Company issued unsecured USD-denominated straight bonds with a total value of US$500 million. The proceeds will be used for general corporate purposes and to refinance part of the funds used to acquire OrganOx. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for securities analysts and institutional investors) |
| Issued Shares at Period-End | 1,480,559,680 |
| Treasury Shares at Period-End | 5,476,639 |
| Factors Behind Changes in Business Performance | Sales remained strong due to continued growth in global healthcare demand, growth in the core businesses, particularly in the Americas, accelerated expansion of the interventional systems business and plasma innovation business, and growth in the pharmaceutical solutions business. |
Items this document does not state (2)
Revision to Earnings ForecastOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The main reasons were continued growth in global healthcare demand, strong sales driven by growth in the core businesses, particularly in the Americas, and an increase in gross profit resulting from higher revenue.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.